FDA Advisory Panel To Review Aveo's Drug

A Food and Drug Administration advisory panel will review Aveo Pharmaceuticals Inc.'s (Nasdaq: AVEO) kidney cancer treatment tivozanib to determine if further study is needed. The stock price plummeted $2.33 to close at $5.11.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.